Literature DB >> 9124410

Contribution of red blood cell aggregation to venous vascular resistance in skeletal muscle.

M Cabel1, H J Meiselman, A S Popel, P C Johnson.   

Abstract

The effects of red blood cell aggregation on venous vascular resistance and conductance were examined in the cat lateral gastrocnemius muscle. During perfusion with blood of normal hematocrit, venous conductance fell linearly by 41% when blood flow was reduced from 5 to 1 ml x min(-1) x 100 g tissue(-1) and increased linearly by 155% when flow was increased from 5 to 20 ml x min(-1) x 100 g tissue(-1). This effect was not seen when the muscle was perfused with an acellular solution of 12% Dextran 40 in Ringer solution and was greatly reduced or absent with a nonaggregating suspension of red blood cells in Ringer solution + Dextran 40. Also, the venous vascular conductance at a control flow of 5 ml x min(-1) x 100 g tissue(-1) during perfusion with the nonaggregating red blood cell suspension was twice that with normal blood of the same hematocrit. The effect of flow on venous conductance was significantly reduced when red blood cell aggregation was increased by addition of Dextran 250 to the blood (200 mg/kg body wt) and was also reduced in animals with systemic hematocrit >50%. These findings suggest that red blood cell aggregation contributes importantly to venous vascular resistance in resting muscle.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9124410     DOI: 10.1152/ajpheart.1997.272.2.H1020

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  19 in total

1.  Kinetics of linear rouleaux formation studied by visual monitoring of red cell dynamic organization.

Authors:  G Barshtein; D Wajnblum; S Yedgar
Journal:  Biophys J       Date:  2000-05       Impact factor: 4.033

2.  Microcirculation and Hemorheology.

Authors:  Aleksander S Popel; Paul C Johnson
Journal:  Annu Rev Fluid Mech       Date:  2005-01-01       Impact factor: 18.511

3.  Time to rheology in acute myocardial infarction: inflammation and erythrocyte aggregation as a consequence and not necessarily as precursors of the disease.

Authors:  Arie Steinvil; Shlomo Berliner; Itzhak Shapira; Ori Rogowski; Dan Justo; Jacob George; Amir Halkin; Gad Keren; Ariel Finkelstein; Shmuel Banai; Yaron Arbel
Journal:  Clin Res Cardiol       Date:  2010-05-15       Impact factor: 5.460

4.  Effects of dextran molecular weight on red blood cell aggregation.

Authors:  Björn Neu; Rosalinda Wenby; Herbert J Meiselman
Journal:  Biophys J       Date:  2008-06-27       Impact factor: 4.033

5.  Depletion-mediated red blood cell aggregation in polymer solutions.

Authors:  Björn Neu; Herbert J Meiselman
Journal:  Biophys J       Date:  2002-11       Impact factor: 4.033

6.  The effect of red blood cell aggregation on velocity and cell-depleted layer characteristics of blood in a bifurcating microchannel.

Authors:  J M Sherwood; J Dusting; E Kaliviotis; S Balabani
Journal:  Biomicrofluidics       Date:  2012-05-11       Impact factor: 2.800

7.  Depletion interactions in polymer solutions promote red blood cell adhesion to albumin-coated surfaces.

Authors:  Björn Neu; Herbert J Meiselman
Journal:  Biochim Biophys Acta       Date:  2006-09-15

8.  Inflammation-related erythrocyte aggregation in patients with inflammatory bowel disease.

Authors:  Liaz Zilberman; Ori Rogowski; Meirav Rozenblat; Itzhak Shapira; Jacob Serov; Pinhas Halpern; Iris Dotan; Nadir Arber; Shlomo Berliner
Journal:  Dig Dis Sci       Date:  2005-04       Impact factor: 3.199

9.  Computational study for the effects of coil configuration on blood flow characteristics in coil-embolized cerebral aneurysm.

Authors:  Tomohiro Otani; Satoshi Ii; Tomoyoshi Shigematsu; Toshiyuki Fujinaka; Masayuki Hirata; Tomohiko Ozaki; Shigeo Wada
Journal:  Med Biol Eng Comput       Date:  2016-07-21       Impact factor: 2.602

10.  Increased ability of erythrocytes to aggregate in spontaneously hypertensive rats.

Authors:  David Lominadze; Dale A Schuschke; Irving G Joshua; William L Dean
Journal:  Clin Exp Hypertens       Date:  2002-07       Impact factor: 1.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.